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ABSTRACT
Introduction: Medicinal products of a biological origin are approved by the EMA at a centralized level.
However, there is no harmonization about their use in Europe. The current regulation referring to the
safety of biological medicinal products and biosimilars in Europe has been identified. The safety
associated with medicinal products of a biological origin is assured by the pharmacovigilance system,
which has evolved, but doesn’t yet incorporate all of the specific information from this market segment,
namely that related to the identification of drugs, and its use – including the prescription and
dispensing, given the possibility of interchangeability and substitution. The terminology, information
systems and traceability systems aren’t entirely appropriate to ensure the safety requirements for
therapy with medicinal products of a biological origin.
Areas covered: This article aims to identify the prescription and dispensing profiles of reference
biological medicines and biosimilars in the EU, and the determinants that support their safe use.
Expert opinion: The European pharmacovigilance system must evolve to ensure the safety along all of
the biologicals’ therapeutic cycle. It must consider the safety for each of the medicines in addition to
their safety pattern related to the eventual switching procedure.
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The approval of biologicals by a centralized procedure is fol-
lowed by additional safety monitoring [1], and their utilization is
usually based on national regulations. The safe use of biologi-
cals in the European Union (EU) can be improved by efficient
coordination between European and national regulations.
Because the manufacturing of reference biologicals and
biosimilars is based on cells and living organisms, their varia-
bility depends upon manufacturer-specific conditions, which
can impact their efficacy and safety [2,3]. The practice of
interchangeability between reference biologicals and biosimi-
lars can sustain increasing pharmaceutical expenditures [4,5].
To continuously ensure safety, the pharmacovigilance system
must follow updated technical and scientific knowledge [6].
Additionally, clinical practice related to biosimilars can impose
new legislation, due to the nonspecificity of current one [7,8].
The European Medicines Agency (EMA) was the first institu-
tion in the world to establish regulatory guidelines for safety
assessments of biological medicinal products during the premar-
keting authorization phase. Additionally, EMA also established
guidelines for biosimilars, which led to the approval of the first
biosimilar in 2006 [9–12] (Table 1). The approval of the first
biological product occurred in 1980. However, EMA and WHO
consider that during themarketing phase, prescribing guidelines
should be issued by the authorities of each Member State. It was
only in 2009 that the Food and Drug Association (FDA) recog-
nized biosimilar status with the publication of the Biologics Price
Competition and Innovation Act. Later, by 2017, the publication
of ‘Considerations in demonstrating interchangeability with a
reference product – Guidance for industry’ provided new gui-
dance related to switching studies for drugs intended to be
administered more than once [13]. The FDA also classified
drugs covered by interchangeability [14,15]. In the EU, each
Member State defines the requirements for interchangeability
and substitution. In international settings, the terminology of
biosimilars is diverse (Table 2) [16–20].
The safety of biologicals requires traceability of the patient
as well as of the drug’s basic components and raw materials.
Regulation 1394/2007 of 13 November covers the drug’s
entire life cycle, from the source of the recombinant cell and
raw materials until its final use by the patient. A decision
concerning the drug’s safety is made according to the severity
of adverse reactions (Table 3) [21].
Reports of suspected adverse reactions are required from the
marketing authorization (MA) holder, health-care professionals,
and patients. The Eudravigilance database centralizes data and
allows effective safety coordination in the EU. This monitoring
unfolds through the activities of ‘detection, assessment, minimiza-
tion and communication relating to the risk of adverse reactions,
while taking the therapeutic effect of the medicine for human use
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into account, and the responsibility for the design and evaluation
of post-authorization safety studies and pharmacovigilance audits’
[22]. The Pharmacovigilance Risk Assessment Committee (PRAC)
aims to foster peer-to-peer communication and the taking of joint
positions. PRAC, along with the Coordination Group of
Pharmacovigilance Activities, provides information to the
Committee for Medicinal Products for Human Use.
Specific regulations allow continuous monitoring of the
benefit–risk ratio of the drug, the functioning of the risk
management system, monitoring of the results and measures
undertaken for risk minimization, collection and evaluation
activities and communication of safety reports related to indi-
vidual cases, procedures for preparation and submission of
periodic safety reports, and procedures for communication
with health-care professionals and the public at the time of
risk identification; risk identification requires the adoption of
measures affecting the use of medicines [23].
Risk management plans are usually required for biosimilars
[18,22]. Post-authorization safety studies can be included to
allow for real-world use data, which can support the with-
drawal of MA (Table 4) [24,25].
Because there is segmentation of risk among drugs, an
additional monitoring system was needed to cover medicinal
products containing a new active substance, biological med-
icinal products and biosimilars, and products requiring post-
authorization data. To enable the prompt identification of
medicinal products subjected to additional monitoring –
either by patients or health-care professionals – the use of a
black inverted equilateral triangle on the product’s packaging
was recommended [22].
Additionally, the use of a unique standardized identifier is
considered an adequate procedure for coping with risk man-
agement [26]. These identifiers can ensure the identification,
localization, and authentication of medicinal products in
Europe. This system will be in force from February 2019.
Specific safety concerns related to crossborder health care
and traceability require the implementation of regulations
related to medical prescriptions, which must address the
trade name, dosage form, quantity, dose, and dosage [27].
2. Interchangeability and substitution in European
countries
The criteria for the prescribing of medicines are based in each of
the Member States, as prescriptions are one of the most impor-
tant pathways for accessing the genericmarket [28]. Additionally,
interchangeability and substitution are regulated for biosimilars
and can be considered for different MA holders. The definition of
biosimilars, and following patterns of switching, will impact on
market share because prescription by International Non-
Article highlights
● Biologicals and biossimilars have centralized approval by EMA
● Switching (interchangeability and substitution) is regulated by
Member States
● Safety assessment of biologicals relies on pharmacovigilance data
both pre-and post marketing
● The pharmacovigilance system oversees each drug’s benefit-risk
assessment
● Potential risks related to switching are not adequately assessed in
Europe due to the absence of specific safety tools
This box summarizes key points contained in the article.
Table 1. Regulatory framework for biosimilars approval by EMA and FDA [10–13].
EMA (Europe) FDA (United States)
Biosimilars approval: Based on
demonstration of the similarity in




Biosimilars approval: Based on the
demonstration of similarity in terms
of safety, purity, and potency
Interchangeable approval: Based on
the demonstration of similarity, and
data or information about provision
of the same clinical result as the
reference drug
Evidence generated by similarity
based on comparability studies
Evidence generated by similarity or
interchangeability studies
Intends to provide the basis for the
approval based on a reference
product
Intends to provide the basis for the
approval based on a reference
product
Evaluation of biosimilars does not
consider interchangeability neither
substitution considerations
Evaluation allows for the approval of
biosimilars and for interchangeable
drugs (i.e. drugs that may
substitute reference drugs without
the intervention of the prescriber of
reference product)
Table 2. Worldwide designation of biological and biosimilar drugs [16–20].
Designation Country Characteristics











Precedent biotechnology drug Japan Biosimilars
Biopharmaceuticals NA Drug products that contain biotechnology derived proteins as active pharmaceutical ingredients
Biopharmaceutical products not subject to
regulatory approval (B-NSRA)
NA
Bioidenticals NA Same product (‘same vessel’ in terms of active pharmaceutical ingredient, device might be
different) sold under different brand names by different companies
Biobetters or biosuperiors NA Drugs that are similar to innovator biologics but are characterized by some change in the
structure of the protein or the process by which they are made, with the goal of improved
efficacy, safety, or immunogenicity
Superbiosimilars NA Second generation versions of biosimilars, the development of which will drive the longer term
market growth
FOPs: Follow-on protein products; FoBs: follow-on biologics; SEB: subsequent-entry generics; SBMPs: similar biotherapeutic products; RBP: reference biotherapeutic product.
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Proprietary Name (INN) has been mandatory in some European
countries since 2004 (specifically, in Spain, France, Italy, Ireland,
the United Kingdom, Estonia, and Malta) [29]. This legislation
enables interchangeability, allowing the original or a biosimilar
drug to be dispensedwithout distinction [30]. However, there are
problems that should be prevented, such as unintentional sub-
stitution as well as the practice of interchangeability, which must
be based on scientific evidence [31].
Interchangeability and substitution should be based on
regulations and should be able to add clarity to clinical prac-
tice [32]. Usually, interchangeability is not recommended if the
patient is stable from a clinical point of view [33]. However,
this issue is only relevant if the efficacy and safety patterns of
biosimilars have a clinical impact [34]. In such cases, drugs are
not interchangeable [35].
Substitution has different requirements in different states;
these differences are misleading and require careful assessment.
Substitution can be related to the practice of prescribing by INN,
to the substitution by a biosimilar when dispensing at pharma-
cies, and to interchangeability among biosimilars or between
original biologicals and biosimilars. Nonetheless, there is a
broad concept that relates interchangeability to the practice of
prescribing and relates substitution to the practice of dispensing.
Regulations in France, Germany, and Spain do not allow the
automatic substitution of biologicals, by 2011 [36]. Because
they are different medicines, substitution between biosimilars
should not occur [37].
The literature reports that exact replication and consistent
manufacturing of biologicals is a challenge, and guidelines
allow the evaluation of biosimilars [38]. Comparability and simi-
larity are central topics: the first aims to confirm physical–chemi-
cal and biological specifications between different batches of the
same product, while the second intends to ensure similarity
between the biosimilar and the reference product [39].
According to EMA, the authorization of interchangeability
and substitution is a responsibility of the states. In contrast,
the FDA classifies interchangeable biosimilars as well as those
that are new active substances for which interchangeability
with the reference medicinal product is not allowed [40].
Different regulations support both.
In Europe, interchangeability between the reference medicinal
product and biosimilars is generally accepted, contrary to what
occurs with substitution. In fact, due to the traceability of adverse
reactions associated with the reference product, substitution by
biosimilars should not be immediate [41]. Most European states
do not allow automatic substitution, having excluded biosimilars
from their lists of medicines for substitution [42]. By the contrary,
interchangeability is entering into force.
For the European Generics Association, interchangeability
‘refers to the medicinal/pharmaceutical practice of switching
one medicine for another that is equivalent, in a clinical set-
ting. A product is considered interchangeable if it can be
administered or dispensed instead of another clinically
approved product’ whereas ‘substitution refers to the practice
of dispensing . . . at pharmacy level and without consultation
of the prescriber’ [31]. The WHO defines interchangeability as
‘the medical practice of switching one medicine for another
that is equivalent, in each clinical setting’ and adds that ‘the
decision to allow automatic substitution of a similar biother-
apeutic product for a reference biotherapeutic product should
be made on a national level taking into account potential
safety issues with the product or class of products’ [31].
Usually, automatic substitution by biosimilars is not
allowed. However, this pattern has been changing [43].
There are various approaches, including MA using the same
original product, the same manufacturer, or the same manu-
facturing process [44]. Considering current evidence, some
authors see no risks in interchangeability [45].
Belgium does not allow either interchangeability or substi-
tution of the prescribed medicine [41]. In Denmark, interchan-
geability and substitution occur under the terms of MA
approval, which requires the demonstration of similarity. It is
assumed that there are no differences in the medicines’ safety
or efficacy profiles [46].
In Spain, biological medicinal products are not covered by
the principles of interchangeability and substitution [47,48]. In
2006, published legislation required the systematic use of the
INN for prescription purposes; in 2013, it was decided that the
brand name should be employed preferentially [49].
Based on official information, interchangeability and substi-
tution are accepted in Finland if there are no increased adverse
effects associated with any of these procedures [50,51].
Substitution takes place only among drugs that are part of a
list published quarterly by the MA [41]. The registry of informa-
tion associated with interchangeability and substitution, namely
the brand name and batch number, should be assured [47].
In France, the framework for the utilization of biologicals
has evolved since 2007, when the unique identity of these
drugs was first recognized and the differences between biosi-
milars and the original medicines were made clear; automatic
substitution was prohibited until 2014 [52]. However, France
was the first country to allow substitution in pharmacies, but
only at the beginning of treatment [39]. However, the medi-
cines must be in the same biologic group, and the prescriber
Table 4. Drug and market interventions following adverse reactions [24].
Severity of adverse reaction Intervention
Minor Inclusion of a new contraindication
Dose reduction
Restriction of therapeutic indications
Major MA suspension or revocation
Drug delivery interdiction
MA renewal rejection
Table 3. Adverse reaction, serious adverse reaction, and unexpected adverse
reaction definition.
Name Definition
Adverse reaction Refers to ‘A response to a medicinal product which is
noxious and unintended and which occurs at doses
normally used in man for the prophylaxis, diagnosis
or therapy of disease or for the restoration, correction
or modification of physiological function’ [6].
When the adverse reaction results from ‘medication




When results in death or is life-threatening
Unexpected
adverse reaction
When there is not consistency with Summary of Product
Caractheristics (SmPC) information
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must agree with the substitution [39,41]. Once the treatment
is ongoing, substitution is not allowed in any case [41]. In the
Netherlands, interchangeability is allowed only under specific
conditions that ensure safety [53,54]. In Italy, automatic sub-
stitution is not allowed [40].
In Portugal, the Centros Prescritores de Agentes Biológicos
(Centres for Biologicals Prescription) – registered in ‘Direção
Geral da Saúde’ – ensure monitoring activities [55]. INFARMED
(the Portuguese Medicines Authority), through the ‘Comissão
Nacional de Farmácia e Terapêutica’ (National Pharmacy and
Therapeutics Committee), published a document that guides
the prescription of biologicals; interchangeability is considered
in specific situations, but substitution is not [56].
In the United Kingdom, brand-name drugs are preferred.
Moreover, hospitals are encouraged to disclose favorable
results achieved using biosimilars [40]. Substitutions must
only take place when accompanied by a reasoned decision
made by the prescriber [41]. In Sweden, there is an official list
of drugs that may be subject to substitution, but biosimilars
are not included on that list due to their complexity [41]. The
utilization criteria for biological medicinal products in the EU
are summarized in Table 5.
3. The terminology of biologicals
The management of the information that contributes to safety
reports relies on a general nomenclature. While original drugs
are well characterized by their brand names, biosimilars rely on
the INN. The WHO proposes that the MA holder and batch
number must also be considered. In fact, if there is no accurate
terminology to differentiate among biosimilars, there will be
confusion regarding naming when trying to establish causality
related to adverse events. Additionally, the nomenclature should
be the same in all countries to allow traceability [29,57].
Currently, INN allocation requests for biological medicinal pro-
ducts account for 40% of all submissions to the WHO [58].
To overcome the limitations of the current system and
ensure accurate identification of biologicals, the WHO estab-
lished the system of biological qualifiers, which ‘is a random
alphabetic code assigned to a biological active substance on
application by a biological qualifier (BQ) applicant and used in
medicines distributed by a Marketing Authorisation Holder.’
The allocation must occur in both directions, both prospec-
tively and retrospectively [57]. Biological qualifiers consist of
four randomized consonants, used after the brand name or
INN. The biological qualifier will be used if the same amino
acid sequence and the same INN are maintained. The use of
biological qualifiers must ensure the identification of biologi-
cal substances related to prescribing and dispensing; this
practice is intended to facilitate pharmacovigilance and to
support the transfer of medication prescriptions [57].
4. Risk and traceability
Due to the controlled conditions of clinical trials, the safety and
efficacy profiles of a drug are incomplete at the time of MA [59].
Pharmacovigilance enables the identification and definition of
the risks related to the use of drugs in real-world conditions [41].
This information can support the conditions of interchangeabil-
ity and substitution, as well as their background methodologies
[32]. However, clinical trials that are capable of specifically eval-
uating switching-related risks are still currently lacking in Europe.
It was found that 3 years after their marketing approval, 14% of
medicines are subject to interventions, a figure that increases to
29% after 10 years [57]. Moreover, the first medicines belonging
to a new therapeutic class are associated with an increased
prevalence of adverse events [60].
Biologicals carry the potential risk of immunogenicity [61,62].
However, there are also risks of autoimmunity and potential
diversity of efficacy, mainly for biosimilars [19]. According to
other authors, the safety profile of biologicals indicates that most
of their adverse effects are due to their biological activity and not
to an immunologic response such as hypersensitivity. The risk can
also be modified by the presence of contaminants [28]. However,
risks are also related to the drug’s exposure, route of administra-
tion, therapeutic indication, and severity of the disease [19].
A specific classification for the reporting of adverse reac-
tions associated with biologicals has been developed [63].
When side effects do not show a temporal coincidence with
the use of medicines, it is normal to find a reduced number of
notifications of suspected adverse reactions. In such a case,
the role of pharmacists is essential and relevant, as society
depends on them to ensure the traceability of biologicals [28].
The traceability of biologicals can be ensured through an
integrated individual record of prescriptions or through the
enrolment of patients in an observatory for monitoring. The
literature also proposes establishing a serologic library with
registries of the development of antibodies associated with
the administration of drugs of different brands [64].
5. Conclusion
The European MA of biologicals is centralized by the EMA.
However, this institution does not comment on the criteria for
the use of these products. Rather, it allows each Member State
to rule on this topic.
Biosimilar drugs are approved after the patent on the original
product expires. Although they do have the same active ingredi-
ent, dose, and pharmaceutical formulation, biosimilar drugs are
not equivalent to the original drug in the same way that generics
are identical to the reference drug, but they are similar. This fact
stems from the nature and complexity of biologicals, whose man-
ufacturing process explains the variability among different
batches of the same drug and among medicines obtained from
Table 5. European pattern related with interchangeability and automatic
substitution.




France Allowed with restrictions Allowed with restrictions
Germany Allowed with restrictions Allowed with restrictions
Italy Allowed with restrictions Not allowed
Netherland Allowed with restrictions Not allowed
Portugal Allowed with restrictions Not allowed
Spain Not allowed Not allowed
Sweden Not allowed Not allowed
United Kingdom Strictly allowed Not allowed
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different manufacturers or MA holders. A systematic review of the
literature notes the theoretical possibility of the occurrence of
changes in the efficacy and safety profiles between the original
biologicals and biosimilars. However, robust data from scientific
evidence is still lacking.
Based on these facts, the positions of Member States regard-
ing the preferential option for original biologicals or biosimilars
are not uniform. Although European centralized approval allows
the marketing of these products simultaneously among Member
States, there is no consistency among the dates of effective
marketing, nor about entry into force of the positions assumed,
neither is there uniformity across selected regulatory instru-
ments. An evolution in the positions assumed by some countries
has also been observed, from very conservative and constrained
postures toward the use of these drugs to more diversified
positions toward the selection of original biological or biosimilar
drugs. This development has been accompanied by the imple-
mentation of additional measures to reinforce monitoring, to
provide information to health-care professionals, and to establish
procedures, collection systems, and information analyses to
strengthen future decision criteria based on scientific evidence.
The regulatory interventions that have been considered
came from two fundamental perspectives: therapeutic and
economic. The first is always observed and is based on the
terms of interchangeability and substitution patterns that
must be followed to guarantee the safety and efficacy of
biological therapy, while the second is only observed for
some of the states and is based on financing typologies of
biologicals and related incentives.
For most states, the positions assumed in the areas pre-
viously identified were formalized through guidance docu-
ments issued by the Medicines Authorities, which can be
updated as scientific evidence becomes available.
Regardless of the regulatory tools that are used, the key
factor affecting the choice between original biologicals and
biosimilars – whether based on interchangeability or substitu-
tion – is always patient safety. Due to this, healthcare profes-
sionals should be able to access registries related to previous
data about patients’ biological therapies.
Therapy with reference drugs should be the rule in com-
plex and severe cases, once the patient is stabilized. If the
practice of interchangeability can be accepted in duly identi-
fied specific situations, substitution must be discouraged in
dispensing medications of biological origin.
Opting for interchangeability and substitution practices
requires the establishment of monitoring and surveillance
systems appropriate to the nature of the therapy. The creation
of robust scientific evidence is also required. For this purpose,
the adoption of terminology and of analytical criteria appro-
priate to the characterization of specific adverse effects of
biological medicinal products must be considered. Also
worth considering is the creation of a track record of the use
of drugs of biological origin in all Member States, as is already
in place in some of them, as this record would enable the
systematization and monitoring of information.
When evaluating suspected adverse drug reactions to biologi-
cals, namely adverse events related to the immune system (poten-
tial immunogenicity, adventitious infection, or autoimmunity), the
patient’s characteristics must be considered. The patient’s
comprehensive records pertaining to biologicals, including the
identification of the manufacturer and batch number in addition
to the active substance, should allow for personalized therapeutic
decisions. These clinical files should also support pharmacovigi-
lance of biologicals.
In addition, a common and more specific terminology must
be in force because the INN system is far from adequate for
documenting the adverse events associated with biologicals.
By extension, an update on the reporting criteria for adverse
reactions related to the interchangeability and substitution of
biologicals should be in force.
A biological’s safety pattern should rely on both retrospec-
tive and prospective information related to adverse reactions
reports; there should be registration of continuous prescrip-
tion data related with the therapeutic cycle, including the
frequency of interchangeability and substitution. The identifi-
cation of patients at potential risk should be regulated.
6. Expert opinion
Biologicals and biosimilars are highly complex molecules that
need to prove similarity based on comparability studies to
gain MA; similarity must be based on the chosen reference
biological product. However, unlike routine use, clinical trials
do not currently address interchangeability and substitution.
There is a gap related to risk assessment based on switching.
The EMA does not provide opinions about interchangeability
and substitution practices because these practices are related
to local utilization practices, which are beyond the scope of
EMA activity. The EMA instead focuses on MA.
In contrast, the pharmacovigilance system is related to the local
utilization of drugs and should be tailored to capturing the risks
related to switching. In fact, no risks will be expected (they will not
be found in the current literature) if there are no tools that allow
their identification. This is the main finding of current research.
There are three main challenges in pursuing this goal: first,
a new nomenclature should be adopted by all European
countries, specific to each batch and manufacturer, allowing
the individualization and identification of each biodrug.
Second, registries must begin to provide information about
switching – including both interchangeability and substitu-
tion. Third, there is a need for research on signals based on
information collected by an updated pharmacovigilance sys-
tem according to the two mentioned suggestions.
In fact, if original biologicals are identified by their brand name,
which is not repeatable, the opposite happens with biosimilar
drugs. As the same INN is used for different biological molecules,
which come from several MA holders and manufacturing pro-
cesses, registries will be unable to differentiate among the various
biosimilars. Consequently, causality assessment and risk evalua-
tion will not be possible, and no safety concerns will be identified
in relation to clinical practice.
In the coming years, personalized therapy will need to be
sustained by accurate data; such therapy is not compatible
with the current unspecific state of the available information.
Safety systems will need to cope with narrower and highly
specific information and will define tailored utilization patterns
for biological therapy.
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In addition, cross-border health care faces other challenges
related to information-sharing across member states. Due to
local regulations on switching, patients will need to cope with
diverse clinical approaches in different countries. This will preclude
not only the sharing of information, safety assessment, identifica-
tionof determinants, but also equity. Suchgapsmust beovercome
by the adoption of common and broader terminology, biological
use patterns, and pharmacovigilance registries in Europe.
The related evolution of financing systems – currently based
on population data – is being driven by risk-related data and
patient-reported outcomes – personalized data – and the provi-
sion of care for rare diseases in European reference centers is
mainly based on biological therapy. Biologicals are also repla-
cing chemical therapy. Due to these topics, biologicals are
definitively at the center of all stakeholders’ attention.
The protection of public health requires improving the evi-
dence base of the risks of biologicals, which can be accomplished
by new tools and an updated safety regulatory framework.
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